Navigation Links
Media Advisory: ACC Updated Schedule

Schering-Plough Announces Presentation Of Phase II Trial Results For Novel Oral Thrombin Receptor Antagonist At The 2007 Annual Meeting Of The American College Of Cardiology/i2 Summit

KENILWORTH, N.J., March 16, 2007 /PRNewswire-FirstCall/ -- Schering-Plough Corporation announced today that results of the Phase II trial of its novel oral thrombin receptor antagonist (TRA) SCH 530348 will be presented at the 2007 annual Scientific Sessions of the of Cardiology (ACC.07)/Innovation in Intervention (i2) Summit, March 24-27 in New Orleans. The Phase II trial, referred to as the Thrombin Receptor Antagonist in Percutaneous Coronary Intervention (TRA-PCI) trial, has been accepted as a late-breaker presentation.

The trial was designed to evaluate the safety and tolerability of Schering-Plough's TRA coadminstered with standard of care antithrombotic therapy (including aspirin and clopidogrel) in patients undergoing percutaneous coronary intervention (PCI). A secondary objective was to assess whether patients treated with the compound had fewer cardiovascular events such as heart attack, need for urgent coronary revascularization, or death at 60 days compared with patients treated with the standard of care.

TRA Late-Breaker Trial Data Presentation:

Results of a Multinational Randomized, Double-Blind, Placebo-Controlled Study of a Novel Thrombin Receptor Antagonist SCH 530348 in Percutaneous Coronary Intervention, David J. Moliterno, MD, Chief of Cardiovascular Medicine, University of Kentucky School of Medicine, for the TRA-PCI Investigators, Saturday, March 24, 11:45AM - 11:55AM, Ernest N. Morial Convention Center, La Nouvelle Orleans C.

Dr. Moliterno will participate in the ACC press conference immediately following (12:00PM - 1:00PM) in Rooms 215-216, just above Hall A.

About Schering-Plough Corporation

Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its approximately 33,500 people around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

CONTACT: Media Contact, Lee A. Davies, +1-908-298-7127, or InvestorContact, Alex Kelly, +1-908-298-7436

Web site: http://www.schering-plough.com/

Company News On-Call: http://www.prnewswire.com/comp/777050.html /

Ticker Symbol: (:SGP)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
2. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
3. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
4. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
5. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
6. Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II trial of Cloretazine (VNP40101M) in Patients with Relapsed or Refractory Small Cell Lung Cancer
7. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
8. Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia Long-Term Safety Data at AAN Annual Meeting
9. Boston Scientific Announces Schedule for EuroPcr 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2017)... Corp. (NASDAQ: DRIO), a leading global digital health company with mobile ... presenting at the 7th annual LD Micro Invitational on Tuesday, June ... of DarioHealth will be giving the presentation and meeting with investors. ... 7th, 2017 at the Luxe Sunset Bel Air Hotel and will ... About LD Micro LD Micro was founded ...
(Date:5/26/2017)... plc (NASDAQ: ENDP ) announced today that ... in a fireside chat at Goldman Sachs, 38 th ... 10:40 a.m. PT / 1:40 p.m. ET. The conference will ... Verdes, CA. A live webcast and ... Company,s website at http://www.endo.com/investors/overview . Participants should allow approximately ...
(Date:5/22/2017)... , May 22, 2017  Lilac Corp, the ... announces the launch of a new website ... results of a clinical study that showed surprising ... with Gene-Eden-VIR/Novirin in individuals suffering from HPV warts, ... that there are no other treatments that clear ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... The Katyl Agency, a locally ... and business owners in and around Lackawanna County, is joining Meals On Wheels ... area. , Meals on Wheels of NEPA provides hand-delivered and nutritious meals to ...
(Date:6/22/2017)... , ... June 22, 2017 , ... Branches, Inc. has ... than $245,000 in grant funding to support its programs focused on providing opportunity to ... was awarded a grant by the Foundation of $15,000 to support its , Climb ...
(Date:6/22/2017)... ... June 23, 2017 , ... Despite its pervasiveness, many ... reviews available that integrate basic science with clinical practice. Now, however, a timely review ... providing clinicians with insight into the etiology of NeuP and educating preclinical scientists on ...
(Date:6/20/2017)... ... June 20, 2017 , ... TwelveStone Health Partners, a ... Nashville-based private equity firm, has invested $3.35 million in the company. , ... Claritas Capital offers the smart money, speed to market and accountability we had ...
(Date:6/20/2017)... ... 2017 , ... Hayes, Inc., a leading provider of unbiased ... 5 Questions to Ask Before Entering the Maze of Genetic Testing .” Authored ... team, the book explores the various types of the more than 65,000 commercially ...
Breaking Medicine News(10 mins):